Skip to main content
. 2022 Aug 11;2022:5411462. doi: 10.1155/2022/5411462

Figure 6.

Figure 6

Schisandrin A suppressed TXNIP/NLRP3 in mice model of DN. (a) TXNIP, NLRP3 and caspase-1 protein expressions, (b) IL-1β levels in mice model of DN, (c) TXNIP, NLRP3 and caspase-1 protein expressions, (d) IL-1β levels in mice model of DN, (e) glomerulus injury (Masson staining), (f) blood glucose, (g) body weight, (h) kidney/body weight, (i) serum creatinine, (j) urea nitrogen, (k) urinary albumin levels, (l) water intake (24 h), and (m, n, and o) IL-6, INF-γ, and TNF-α in mice of DN. Control, sham control mice group; model, STZ-induced mice DN group; low/med/high, mice DN by treatment with 25/50/100 mg/kg of Schisandrin A group; Poly, 50 mg/kg of Schisandrin A group; TXNIP i, TXNIP inhibitor group; TXNIP, TXNIP up-regulation group; ##P < 0.01 versus control group; ∗∗P < 0.01 versus STZ-induced mice DN group; ∗∗∗P < 0.01 versus 50 mg/kg of Schisandrin A group; ###P < 0.01 versus 50 mg/kg of Schisandrin A group.